(MENAFN- Straits Research)
Opioids Market Size & Growth Analysis
The global opioids market size was valued at USD 27.13 billion in 2025 and is projected to grow from USD 27.66 billion in 2026 to USD 32.28 billion by 2034, registering a CAGR of 1.95% during the forecast period from 2026 to 2034. North America dominated the opioids market with a market share of 42.5% in 2025.
The opioid industry is poised for substantial growth due to increasing demand for pain, cough, and diarrhea treatments. Market players are primarily focusing on launching generic versions of various opioid drugs, driving accelerated market expansion throughout the forecast period.
Opioids are medications used to treat severe or persistent pain, such as chronic headaches and backaches, by patients recovering from surgery or experiencing severe pain associated with cancer, as well as by adults and children who have been injured while playing sports or who have been severely injured in falls, auto accidents, or other incidents. Narcotics is another term for opiates. Depending on the patient, the situation, and the type and level of pain, doctors prescribe different types of opioids with varying potencies that can be administered in various ways. Despite the fact that some opioids can be used to treat cough and diarrhea, the majority of opioid prescriptions are used to treat moderate to severe pain. Opioid prescription medications consist of hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and others. Opioids are the most frequently prescribed medications for the treatment of moderate to severe chronic pain. These analgesics are used to treat severe, constant pain in patients with terminal illnesses and to manage pain in cancer patients.
Opioids Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 27.13 Billion
2026 Market Size: USD 27.66 Billion
2034 Projected Market Size: USD 32.28 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 1.95%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 42.5%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 6.28%
Segment Insights
By Application
Leading Segment: Pain Management
Market Share in 2025: 76.4%
By Product Type
Fastest-Growing Segment: Fentanyl
CAGR (2026–2034): 5.74%
Download a Free Sample To learn more about this report,
Opioids Market Trends
Growing Preference for Safer and Ready-to-Administer Opioid Formulations
The opioids market is shifting toward carefully controlled products that improve dosing accuracy and reduce medication errors in hospitals. Manufacturers are introducing prefilled syringes, abuse-deterrent formulations, and lower-dose products for acute pain, surgery, anesthesia, and cancer care. Healthcare providers are also adopting multimodal pain management, where opioids are combined with non-opioid medicines to reduce the total opioid dose. Regulatory authorities are demanding clearer safety information about addiction, overdose, and long-term use. Consequently, companies must balance the continuing clinical need for strong analgesics with tighter prescribing practices, packaging safeguards, education programs, and post-market monitoring.
In July 2025, Hikma Pharmaceuticals launched morphine sulfate injection in 2 mg/mL and 4 mg/mL prefilled syringes in the United States for severe pain requiring opioid treatment.
Opioids Market Dynamics
Market Drivers
Persistent Need for Effective Treatment of Severe and Chronic Pain
Demand for opioids continues because these medicines remain important for managing severe pain that cannot be adequately controlled with other therapies. Cancer treatment, major surgery, traumatic injuries, palliative care, and advanced orthopedic conditions frequently require potent and rapidly acting analgesics. Population aging also increases the number of patients experiencing painful cancers, fractures, and degenerative diseases. Hospital demand is supported by injectable morphine and fentanyl used during anesthesia, intensive care, and postoperative recovery. In addition, methadone and buprenorphine serve important roles in treating opioid use disorder, expanding the market beyond conventional pain management while supporting closely supervised medical use.
In December 2025, SAMHSA guidance confirmed that eligible U.S. patients may receive up to 28 unsupervised take-home methadone doses after 31 days in treatment.
Market Restraints
Addiction Risks and Expanding Availability of Non-Opioid Alternatives
Addiction, respiratory depression, overdose, tolerance, and withdrawal remain major barriers to opioid prescribing and commercial growth. Governments and healthcare systems are encouraging shorter treatment periods, lower doses, prescription monitoring, and the use of alternative therapies whenever appropriate. Manufacturers face stronger warning requirements, liability exposure, controlled-production rules, and costly risk-management obligations. Competition is also increasing from non-opioid medicines that can treat acute pain without activating opioid receptors. These developments may reduce opioid use after common surgeries and injuries. Generic pricing pressure further limits revenue, while insurers may restrict coverage or require prior authorization for certain extended-release and high-potency products.
In January 2025, The U.S. FDA approved Vertex Pharmaceuticals' Journavx, a first-in-class non-opioid medicine for moderate-to-severe acute pain in adults.
Market Opportunities
Expansion of Treatment Access and Development of Safer Therapies
Market opportunities are growing in opioid-use-disorder treatment, abuse-deterrent formulations, overdose reversal, and precisely dosed hospital products. Wider access to methadone and buprenorphine can increase demand through certified treatment programs, community clinics, correctional facilities, and telehealth-supported services. Companies can also develop formulations that resist crushing, dissolving, or injection while maintaining effective pain relief. Prefilled syringes and unit-dose packaging offer additional potential by reducing preparation time, contamination, and dosing mistakes in clinical settings. Research into longer-acting treatments and novel compounds may create products with improved adherence, fewer withdrawal symptoms, and lower misuse potential, particularly in underserved areas with limited addiction-care capacity.
In June 2026, NIH cleared an investigational new drug application supporting a Phase I study of mitragynine as a potential treatment for opioid use disorder.
Market Challenges
Maintaining Medical Access While Preventing Misuse and Diversion
The central challenge is ensuring that patients with severe pain receive appropriate treatment without increasing misuse, diversion, or dependence. Restrictive policies can lower unnecessary prescribing, but overly tight controls may create shortages or delay care for cancer patients, surgical patients, and people receiving palliative treatment. Manufacturers must forecast legitimate demand under government production quotas while maintaining reliable supplies of controlled substances. Illicit fentanyl also complicates public understanding because deaths involving illegally manufactured products may be associated with the wider prescription-opioid category. Companies therefore require strong distribution controls, ongoing surveillance, clinician education, and clear communication to preserve trust and comply with changing regulations.
In July 2025, The U.S. FDA ordered class-wide labeling changes for opioid pain medicines to strengthen warnings concerning long-term use, overdose, misuse, and addiction.
Opioids Market Segmentation Analysis
By Application
Pain management dominated the opioids market with a 76.4% market share and a value of USD 20.73 billion in 2025. The segment is expected to grow at a CAGR of 4.72% during the forecast period. Its strong position is supported by the continuing need to control moderate-to-severe pain among patients undergoing major surgery, cancer treatment, trauma care, and palliative care. Opioids such as morphine, fentanyl, oxycodone, and hydrocodone remain important when other medicines provide insufficient relief. An aging population and the growing burden of painful chronic diseases also sustain demand across hospitals, specialty clinics, and home-care settings.
Cough treatment and diarrhea treatment represent the remaining applications within the market. Codeine-based medicines may be prescribed for severe cough when standard treatments are ineffective, although their use is closely controlled because of sedation, dependence, and respiratory risks. Opioids are also used in selected diarrhea cases because they slow intestinal movement and can help manage persistent symptoms. However, demand across both applications is restricted by tighter prescribing standards and the availability of safer alternatives. Physicians generally reserve opioid medicines for carefully selected patients, while regulators continue to discourage unnecessary exposure, particularly among children and other vulnerable groups.
Request Customization to receive a tailored report.
By Product Type
Fentanyl is the fastest-growing product type, accounting for an 18.7% market share and USD 5.07 billion in value in 2025. The segment is projected to register a CAGR of 5.74% during the forecast period. Its growth is driven by fentanyl's high potency, rapid action, and established use during anesthesia, surgery, intensive care, and severe cancer-pain treatment. Injectable products and transdermal patches support demand across hospitals and long-term care settings. Ready-to-administer formats can also improve dosing accuracy and clinical efficiency. Nevertheless, legitimate fentanyl products remain subject to strict storage, prescribing, distribution, and monitoring requirements because of their serious misuse and overdose risks.
Methadone holds an important position in severe-pain management and opioid-use-disorder treatment, supported by specialized treatment programs and supervised dispensing. Codeine continues to serve selected pain and cough applications, although safety concerns restrict its use among certain patients. Oxycodone remains widely used for pain that requires strong analgesic treatment, while morphine continues to be a standard option in surgery, cancer care, emergencies, and palliative medicine. Hydrocodone is commonly supplied in combination pain products but faces careful prescription monitoring. Other opioid products address specialized clinical requirements, with competition influenced by generic availability, formulation improvements, hospital procurement, regulatory controls, and changing treatment guidelines.
Speak to an Analyst to discuss market opportunities.
Opioids Market Regional Outlook
North America Opioids Market Analysis
North America dominated the opioids market with a market share of 42.5% and a value of USD 11.53 billion. The region is expected to register a CAGR of 4.35% during the forecast period. Its substantial value indicates a well-established commercial position and a significant contribution to overall market revenue. Although its growth rate is below that of Asia Pacific and Latin America, North America remains the largest regional market by a considerable margin. The combination of a strong existing base and steady expansion is expected to preserve its leadership in the global opioids market.
United States Opioids Market Insights
The United States represents an established market for opioid medicines used in severe pain management, surgical care, anesthesia, cancer treatment, palliative care, and opioid-use-disorder treatment. Hospitals, specialty clinics, retail pharmacies, and certified treatment programs support demand for prescription products. At the same time, strict prescribing rules, controlled-substance monitoring, safety labeling, and distribution requirements shape commercial activity. Manufacturers are focusing on accurately dosed injections, prefilled syringes, abuse-deterrent formulations, and risk-management programs. Competition from non-opioid pain medicines is also influencing prescribing decisions, encouraging healthcare providers to reserve opioids for patients whose pain cannot be adequately managed through suitable alternatives.
Canada Opioids Market Insights
Canada's opioids market is influenced by the continuing clinical need for effective treatment of severe, acute, chronic, and cancer-related pain. Hospitals, palliative-care providers, community pharmacies, and specialized addiction-treatment services form important parts of the supply and treatment network. Healthcare authorities emphasize responsible prescribing, patient assessment, prescription monitoring, and careful follow-up to reduce dependence and diversion. Methadone and buprenorphine remain relevant within supervised opioid-use-disorder treatment, while strong analgesics are retained for appropriate medical situations. Market participants must maintain dependable product availability while meeting controlled-drug regulations, pharmacovigilance obligations, labeling requirements, and professional expectations concerning safer and more individualized pain management.
Unlock Regional Insights to access country-level data, & regional trends.
Asia Pacific Opioids Market Analysis
Asia Pacific is the fastest-growing region in the opioids market, with a CAGR of 6.28%. The region accounted for a market share of 19.4% and was valued at USD 5.26 billion. Its growth rate is the highest among all regions included in the analysis, indicating stronger expansion potential over the forecast period. Although its current share and value remain below North America and Europe, sustained growth may strengthen its overall market position. The difference between its present size and leading CAGR suggests that Asia Pacific is moving from a comparatively smaller revenue base toward a more prominent role in the global opioids market.
Japan Opioids Market Insights
Japan's opioids market is shaped by demand for closely supervised pain management in hospitals, cancer-care centers, surgical departments, and palliative-care settings. Physicians generally apply careful patient selection and dosage management because opioid medicines carry risks of dependence, respiratory depression, and other serious adverse effects. An organized healthcare system supports controlled access to morphine, fentanyl, oxycodone, and other products when clinically necessary. Opportunities exist for ready-to-administer injections, transdermal delivery systems, and formulations that improve dosing precision. Suppliers must demonstrate consistent quality, regulatory compliance, secure distribution, and reliable availability while responding to growing interest in multimodal treatment approaches that limit unnecessary opioid exposure.
China Opioids Market Insights
China offers development potential for the opioids market as healthcare providers address severe pain associated with surgery, cancer, trauma, and advanced illnesses. Expanding hospital capabilities and greater attention to appropriate pain relief can support the use of medically necessary opioid analgesics. However, access and prescribing remain carefully controlled because of concerns surrounding misuse, dependence, and diversion. Domestic and international manufacturers must navigate product registration, controlled-drug distribution, institutional procurement, and pharmacovigilance requirements. Demand is likely to center on hospital-administered medicines, palliative care, anesthesia, and specialist treatment. Companies offering reliable supply, clinically practical formulations, and strong healthcare-professional education can improve their position in this regulated environment.
Europe Opioids Market Analysis
Europe held a 27.8% share of the opioids market and reached a value of USD 7.54 billion. The region is projected to grow at a CAGR of 4.12%, representing steady expansion from a substantial existing base. Europe ranks behind North America in market share and value but remains ahead of Asia Pacific, Latin America, and the Middle East and Africa. Its CAGR is the lowest among the listed regions, suggesting a comparatively mature growth pattern. Nevertheless, its meaningful revenue contribution and established market scale are expected to maintain Europe's position as the second-largest regional opioids market throughout the assessment period.
Germany Opioids Market Insights
Germany has an established clinical environment for opioid use in severe pain, cancer care, surgery, and palliative treatment. Physicians follow structured treatment practices that emphasize appropriate medicine selection, careful dosage adjustment, ongoing patient evaluation, and management of adverse effects. Hospital pharmacies, community pharmacies, specialist clinics, and long-term care providers contribute to product demand and distribution. Manufacturers compete through product quality, supply reliability, differentiated delivery formats, and compliance with strict pharmaceutical standards. Interest in multimodal pain management encourages clinicians to combine or compare opioids with non-opioid approaches. Consequently, suppliers must demonstrate clear therapeutic value while supporting responsible use, professional education, and effective safety monitoring.
United Kingdom Opioids Market Insights
The United Kingdom opioids market serves patients requiring strong pain relief following major procedures, serious injuries, cancer treatment, and palliative care. Prescribing decisions are shaped by clinical guidance that encourages regular review, clear treatment goals, and careful consideration of dependence and withdrawal risks. Hospitals, primary-care practices, pharmacies, pain clinics, and addiction-treatment services participate in medicine delivery and patient management. Demand continues for established generic products and hospital formulations, although closer scrutiny of long-term prescribing may limit routine use. Companies can strengthen their presence by supplying dependable products, improving packaging and dosage convenience, supporting prescriber education, and developing therapies that address severe pain with better safety and monitoring features.
Latin America Opioids Market Analysis
Latin America represented 6.1% of the opioids market, corresponding to a value of USD 1.65 billion. The region is anticipated to expand at a CAGR of 4.76%, which is higher than the rates reported for North America, Europe, and the Middle East and Africa. Although Latin America currently has a smaller share and value than the three leading regions, its comparatively stronger growth rate indicates gradual market development. The region remains ahead of the Middle East and Africa in market share, value, and CAGR. Continued expansion may modestly improve Latin America's contribution to the global opioids market over the forecast period.
Brazil Opioids Market Insights
Brazil is an important national market within Latin America for opioid medicines used in hospitals, surgery, oncology, emergency care, and palliative treatment. Demand is influenced by the need to improve access to effective pain relief while maintaining controls that prevent misuse and unauthorized distribution. Public and private healthcare institutions participate in procurement, prescribing, and administration, creating varied commercial channels for manufacturers and distributors. Opportunities exist for affordable generic medicines, injectable formulations, and products suited to institutional care. Market development depends on regulatory approval, secure supply chains, professional training, and consistent availability. Responsible prescribing and patient monitoring remain essential for balancing clinical access with opioid-related safety concerns.
Middle East and Africa Opioids Market Analysis
The Middle East and Africa accounted for a 4.2% market share and a value of USD 1.14 billion in the opioids market. The region is projected to grow at a CAGR of 4.21% during the forecast period. It has the smallest market share and value among the listed regions, while its growth rate is slightly above that of Europe. This combination reflects a limited current revenue base accompanied by steady expansion. Although the region is expected to remain smaller than other markets, its positive CAGR indicates continued development and a gradual increase in demand within the global opioids market over the assessment period.
UAE Opioids Market Insights
The UAE opioids market is primarily supported by hospitals, specialist clinics, surgical centers, oncology services, and palliative-care providers that require controlled access to strong analgesics. Healthcare institutions follow strict procedures for importing, storing, prescribing, dispensing, and documenting controlled medicines. Demand is therefore concentrated in supervised clinical settings where opioids can be administered and monitored appropriately. International pharmaceutical companies can participate through authorized distribution partners and institutional supply arrangements. Opportunities are present for high-quality injectable medicines, transdermal products, and accurately dosed formulations. Success depends on regulatory compliance, secure logistics, dependable inventory management, clinician education, and clear safeguards against diversion, dependence, and inappropriate use.
Opioids Market Competitive Landscape
The opioids market includes large generic-drug manufacturers, specialty pharmaceutical companies, and hospital-injectable suppliers. Teva, Pfizer, Hikma, Mallinckrodt, Endo, Sun Pharma, Amneal, and Fresenius Kabi compete through broad portfolios, manufacturing scale, regulatory approvals, and dependable hospital supply. Competition increasingly centers on prefilled syringes, differentiated delivery systems, generic availability, and products designed to reduce medication errors. Regulatory compliance and controlled-substance security are essential competitive factors, while opioid-related litigation has encouraged portfolio restructuring and stronger risk controls. Companies are also investing in non-opioid pain medicines and addiction treatments, creating a competitive environment that extends beyond conventional analgesic sales.
List of Key and Emerging Players in Opioids Market
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson
Endo International plc
Lupin Limited
Cadila Healthcare Limited
Purdue Pharma L.P.
AbbVie Inc.
Fresenius Kabi
Mallinckrodt Pharmaceuticals
Pfizer Inc.
Rhodes Pharmaceuticals L.P.
Sun Pharmaceutical Industries Limited
Nesher Pharmaceuticals (USA) LLC
Amneal Pharmaceuticals LLC
Trevena Inc.
Aurobindo Pharma Limited.
Key Industry Developments
June 2026: Hikma Pharmaceuticals expanded its injectable opioid product portfolio by introducing additional hospital-focused pain management formulations, strengthening its presence in critical care and acute pain treatment markets.
May 2026: Grünenthal expanded its research and development activities in pain management by advancing innovative approaches for chronic pain treatment, including therapies designed to improve patient outcomes and reduce reliance on traditional opioid-based treatments.
March 2026: Hikma Pharmaceuticals expanded its manufacturing capabilities for injectable medicines, including opioid-based hospital products, through investments in production capacity and quality systems.
January 2026: Mallinckrodt expanded its specialty pharmaceutical portfolio by advancing its pain management product offerings and strengthening supply capabilities for hospital and specialty care applications.
Report Scope
Comments
No comment